Compositions and Methods for Inducing Protective Immunity Against Human Immunodeficiency Virus Infection

Abstract

Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV.

We claim: 
     
         1 . A vaccine combination for administration to a subject, comprising:
 (a) a first composition comprising: (i) a first adenovirus 26 (rAd26) vector encoding the amino acid sequence of SEQ ID NO: 1, (ii) a second rAd26 vector encoding the amino acid sequence of SEQ ID NO: 3, and (iii) a third rAd26 vector encoding the amino acid sequence of SEQ ID NO: 4, and a pharmaceutically acceptable carrier; and   (b) a second composition comprising an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 5 and/or an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 6, and a pharmaceutically acceptable carrier,   wherein the first composition is for initial administration and a subsequent administration to the subject, and wherein the second composition is for the subsequent administration at the same time with the first composition after the initial administration of the first composition to the subject.   
     
     
         2 . The vaccine combination of  claim 1 , wherein the second composition comprises an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 5. 
     
     
         3 . The vaccine combination of  claim 1 , wherein the second composition comprises an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 6. 
     
     
         4 . The vaccine combination of  claim 2 , wherein the second composition further comprises an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 6. 
     
     
         5 . The vaccine combination of  claim 1 , wherein the second composition further comprises an adjuvant. 
     
     
         6 . The vaccine combination of  claim 5 , wherein the adjuvant is aluminum phosphate or a saponin-based adjuvant. 
     
     
         7 . A method of inducing an immune response against a human immunodeficiency virus (HIV) in a subject, the method comprising:
 (a) administering to the subject a first composition comprising: (i) a first adenovirus 26 (rAd26) vector encoding the amino acid sequence of SEQ ID NO: 1, (ii) a second rAd26 vector encoding the amino acid sequence of SEQ ID NO: 3, and (iii) a third rAd26 vector encoding the amino acid sequence of SEQ ID NO: 4, and a pharmaceutically acceptable carrier; and subsequently:   (b, i) administering to the subject a second composition comprising an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 5 and/or an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 6, and a pharmaceutically acceptable carrier; and   (b, ii) administering to the subject the first composition at the same time as administering the second composition.   
     
     
         8 . The method of  claim 7 , wherein the second composition comprises an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 5. 
     
     
         9 . The method of  claim 7 , wherein the second composition comprises an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 6. 
     
     
         10 . The method of  claim 8 , wherein the second composition further comprises an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 6. 
     
     
         11 . The method of  claim 7 , wherein the second composition further comprises an adjuvant. 
     
     
         12 . The method of  claim 11 , wherein the adjuvant is aluminum phosphate or a saponin-based adjuvant. 
     
     
         13 . The method of  claim 7 , wherein the immune response generated is a protective immune response. 
     
     
         14 . The method of  claim 7 , wherein the subject is a human. 
     
     
         15 . A vaccine combination for administration to a subject, comprising:
 (a) a first composition comprising: (i) a first adenovirus 26 (rAd26) vector encoding the amino acid sequence of SEQ ID NO: 1, (ii) a second rAd26 vector encoding the amino acid sequence of SEQ ID NO: 3, and (iii) a third rAd26 vector encoding the amino acid sequence of SEQ ID NO: 4, and a pharmaceutically acceptable carrier;   (b) a second composition comprising an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 5 and/or an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 6, and a pharmaceutically acceptable carrier; and   (c) a third composition comprising one or more MVA vectors together encoding the amino acid sequences of SEQ ID NOs: 1, 3 and 4,   wherein the first composition is for initial administration to the subject, and wherein the second composition is for a subsequent administration at the same time with the third composition after the initial administration of the first composition to the subject.   
     
     
         16 . The method of  claim 15 , wherein the second composition comprises an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 5. 
     
     
         17 . The method of  claim 15 , wherein the second composition comprises an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 6. 
     
     
         18 . The method of  claim 16 , wherein the second composition further comprises an HIV envelope polypeptide comprising the amino acid sequence of SEQ ID NO: 6. 
     
     
         19 . The method of  claim 15 , wherein the second composition further comprises an adjuvant. 
     
     
         20 . The method of  claim 19 , wherein the adjuvant is aluminum phosphate or a saponin-based adjuvant.